Gastroparesis Drugs Market

According to Stratistics MRC, the Global Gastroparesis Drugs Market is accounted for $5.9 billion in 2023 and is expected to reach $8.5 billion by 2030 growing at a CAGR of 5.3% during the forecast period. Gastroparesis drugs are medications used to manage the symptoms of gastroparesis, a condition characterized by delayed emptying of the stomach. These drugs aim to improve gastrointestinal motility and alleviate symptoms such as nausea, vomiting, and bloating. Commonly prescribed medications include prokinetics, such as metoclopramide and domperidone, which help stimulate stomach contractions, as well as antiemetics to control nausea and vomiting.

According to data from clinicaaltrials.gov in December 2022, due to the high prevalence of type 1 and type 2 diabetes, there are 60 ongoing clinical trials for gastroparesis drugs. This demand for such drugs is expected to drive and further fuel the overall market to a certain extent.

Market Dynamics: 

Driver: 

Growing aging population

The growing aging population serves as a significant driver in the gastroparesis drugs market due to the increased prevalence of gastroparesis among elderly individuals. As people age, they are more likely to develop gastrointestinal motility disorders like gastroparesis due to natural changes in digestive function. With a rising number of elderly individuals globally, there is a higher demand for effective treatments to manage gastroparesis symptoms, thus fueling the growth of the market for gastroparesis drugs.

Restraint:

Limited efficacy of current drugs

While medications such as prokinetics and antiemetics are commonly prescribed to manage symptoms, their effectiveness varies among individuals, and some patients may experience minimal relief or adverse side effects. Additionally, drug therapy may not adequately address the underlying causes of gastroparesis, such as neuropathy or diabetes. This limitation underscores the need for alternative treatment options and highlights the complexity of managing gastroparesis effectively. 

Opportunity:

Availability of alternative therapies

As awareness about gastroparesis improves among healthcare professionals and patients, there is a greater likelihood of early diagnosis and treatment initiation. This heightened awareness also drives patient advocacy efforts, increasing demand for effective treatments and supporting research into new therapies. Moreover, it fosters collaboration between healthcare providers, pharmaceutical companies, and patient advocacy groups, leading to the development of comprehensive care strategies and improved access to treatment options for individuals with gastroparesis.

Threat:

Availability of alternative therapies

Alternative treatments such as dietary modifications, acupuncture, and electrical stimulation therapies offer non-pharmacological approaches to managing gastroparesis symptoms. Additionally, surgical interventions like gastric pacemaker implantation provide alternative options for patients who are resistant to medication. These alternative therapies compete with traditional drug treatments, potentially reducing demand for gastroparesis drugs.

Covid-19 Impact: 

The COVID-19 pandemic has impacted the gastroparesis drugs market by disrupting healthcare services and delaying patient diagnoses and treatments. Additionally, supply chain disruptions have affected the availability of medications, leading to shortages and supply chain challenges. However, increased awareness of gastrointestinal issues due to the pandemic may drive demand for gastroparesis drugs in the long term.

The prokinetic agents segment is expected to be the largest during the forecast period

The prokinetic agents segment is anticipated to be the largest in the gastroparesis drugs market during the forecast period due to their effectiveness in improving gastrointestinal motility. Drugs such as metoclopramide and domperidone are commonly prescribed to stimulate stomach contractions and accelerate gastric emptying in gastroparesis patients. Additionally, ongoing research and development efforts to enhance the efficacy and safety profiles of prokinetic agents further support their dominance in the market segment.

The injectable segment is expected to have the highest CAGR during the forecast period

The injectable segment is forecasted to experience the highest growth rate in the gastroparesis drugs market during the forecast period. This growth is attributed to the advantages of injectable formulations, such as rapid onset of action and increased bioavailability compared to oral medications. Additionally, injectable drugs offer a more consistent and reliable delivery mechanism, making them preferable for patients with severe gastroparesis symptoms who may have difficulty swallowing oral medications.

Region with largest share:

North America is positioned to sustain its dominance in the gastroparesis drugs market due to a high prevalence of gastroparesis in the region, advanced healthcare infrastructure, and robust research and development activities. Moreover, the presence of key pharmaceutical companies and healthcare providers specializing in gastrointestinal disorders contributes to the market's growth. Additionally, favorable reimbursement policies and increasing awareness of gastroparesis among healthcare professionals and patients further solidify North America's leading position in the market.

Region with highest CAGR:

Asia Pacific is poised for rapid growth in the gastroparesis drugs market owing to the rising prevalence of gastrointestinal disorders, increasing healthcare expenditure, and improving access to healthcare facilities across the region. Furthermore, growing awareness among healthcare professionals and patients about gastroparesis and its management fuels market expansion. Additionally, expanding pharmaceutical infrastructure, rising disposable incomes, and government initiatives to improve healthcare access contribute to the favorable conditions for market growth in Asia Pacific.

Key players in the market

Some of the key players in Gastroparesis Drugs Market include AbbVie Inc., Allergan plc, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Evoke Pharma, Inc., Ferring Pharmaceuticals Inc., GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Processa Pharmaceuticals, Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd. and Vanda Pharmaceuticals Inc.

Key Developments:

In December 2022, Evoke Pharma, Inc. announced that the United States Patent and Trademark Office (USPTO) issued a United States patent No. 11,517,545 under the title 'Treatment of Moderate and Severe Gastroparesis'' which covers the usage of GIMOTI.

In August 2022, Processa Pharmaceuticals, Inc. initiated its Phase 2A clinical trial for PCS12852, enrolling its first patient with moderate to severe gastroparesis.

In April 2022, Processa Pharmaceuticals, Inc. enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis.

In February 2022, Vanda Pharmaceuticals Inc. (Vanda) shared the Phase III clinical trial outcomes, VP-VLY-686-3303, revealing the effectiveness and safety of tradipitant in addressing gastroparesis symptoms.

Disease Types Covered:
• Diabetic Gastroparesis
• Idiopathic Gastroparesis
• Post-Surgical Gastroparesis
• Other Disease Types

Drug Classes Covered:
• Prokinetic Agents
• Antiemetic Agents 
• Other Drug Class

Route of Administrations Covered:
• Oral
• Injectable
• Intravenous

Distribution Channels Covered:
• Ambulatory Surgical Centers
• Hospitals
• Retail Pharmacies
• Other Distribution Channels

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances